Found 100 with Last Name = 'kawanishi' and Initial = 'e' 
Affinity DataKi: 56nMAssay Description:Irreversible inhibition of recombinant full length SARS-CoV-2 3CLpro expressed in Escherichia coli using Ac-Abu-Tle-Leu-Gln-MCA as fluorogenic substr...More data for this Ligand-Target Pair
Affinity DataKi: 224nMAssay Description:Irreversible inhibition of recombinant full length SARS-CoV-2 3CLpro expressed in Escherichia coli using Ac-Abu-Tle-Leu-Gln-MCA as fluorogenic substr...More data for this Ligand-Target Pair
Affinity DataIC50: 0.00450nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.00680nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.00850nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0190nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0350nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0440nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0450nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0520nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Affinity DataIC50: 0.0610nMAssay Description:Inhibition of human N-terminal FLAG-tagged PDE10A (1 to 90 residues) expressed in using African green monkey COS7 cells using [3H]cAMP or [3H]cGMP as...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Affinity DataIC50: 0.0620nMAssay Description:Inhibition of human N-terminal FLAG-tagged PDE10A (1 to 90 residues) expressed in using African green monkey COS7 cells using [3H]cAMP or [3H]cGMP as...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0900nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.0900nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.110nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Affinity DataIC50: 0.120nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.130nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.150nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Affinity DataIC50: 0.150nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.170nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.180nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Affinity DataIC50: 0.180nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.200nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.220nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.230nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Affinity DataIC50: 0.270nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Affinity DataIC50: 0.280nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.320nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.360nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.380nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.390nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.390nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.460nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.480nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.570nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Affinity DataIC50: 0.600nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Affinity DataIC50: 0.640nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.650nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Affinity DataIC50: 0.690nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.780nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.790nMAssay Description:Inhibition of recombinant full length SARS-CoV-2 3CLpro expressed in Escherichia coli using Ac-Abu-Tle-Leu-Gln-MCA as fluorogenic substrate preincuba...More data for this Ligand-Target Pair
3D Structure (crystal)
Affinity DataIC50: 0.800nMAssay Description:Inhibition of human SGLT2 expressed in CHOK cells assessed as reduction of [14C]alpha-methyl-D-glucopyranoside uptake after 120 mins by liquid scinti...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Affinity DataIC50: 0.820nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.830nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 0.870nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Mitsubishi Tanabe Pharma
Curated by ChEMBL
Affinity DataIC50: 0.890nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of human SGLT2 expressed in CHOK cells assessed as reduction of [14C]alpha-methyl-D-glucopyranoside uptake after 120 mins by liquid scinti...More data for this Ligand-Target Pair
Affinity DataIC50: 1.08nMpH: 8.0Assay Description:The PDE assay was performed according to a modified method referred to a report of Kotera et al. (Kotera et al., Biochem. Pharmacol., vol. 60, pp. 13...More data for this Ligand-Target Pair
Affinity DataIC50: 1.5nMAssay Description:Inhibition of human SGLT2 expressed in CHOK cells assessed as reduction of [14C]alpha-methyl-D-glucopyranoside uptake after 120 mins by liquid scinti...More data for this Ligand-Target Pair
Affinity DataIC50: 1.70nMAssay Description:Inhibition of recombinant full length SARS-CoV-2 3CLpro expressed in Escherichia coli using Ac-Abu-Tle-Leu-Gln-MCA as fluorogenic substrate preincuba...More data for this Ligand-Target Pair
